SEphB4-HSA
- Generic Name
- SEphB4-HSA
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- SO0RV2V6EJ
- Background
SEphB4-HSA is under investigation in clinical trial NCT02495896 (Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors).
- Associated Conditions
- -
- Associated Therapies
- -
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Vasgene Therapeutics, Inc
- Target Recruit Count
- 700
- Registration Number
- NCT06493552
A Study of sEphB4-HSA in Kaposi Sarcoma
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Vasgene Therapeutics, Inc
- Target Recruit Count
- 65
- Registration Number
- NCT03993106
- Locations
- 🇺🇸
CAN (Community AIDS Network) Community Health, Sarasota, Florida, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸AIDS Healthcare Foundation, Beverly Hills, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath